CN1709439A - Ginseng and astragalis blood glucose loucring dorpping pill, and its preparing and detecting method - Google Patents
Ginseng and astragalis blood glucose loucring dorpping pill, and its preparing and detecting method Download PDFInfo
- Publication number
- CN1709439A CN1709439A CN 200510080654 CN200510080654A CN1709439A CN 1709439 A CN1709439 A CN 1709439A CN 200510080654 CN200510080654 CN 200510080654 CN 200510080654 A CN200510080654 A CN 200510080654A CN 1709439 A CN1709439 A CN 1709439A
- Authority
- CN
- China
- Prior art keywords
- water
- solution
- weight portion
- ginsenoside
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000006187 pill Substances 0.000 title claims abstract description 48
- 241000208340 Araliaceae Species 0.000 title claims abstract description 13
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title claims abstract description 13
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims abstract description 13
- 235000008434 ginseng Nutrition 0.000 title claims abstract description 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title claims description 51
- 239000008103 glucose Substances 0.000 title claims description 50
- 239000008280 blood Substances 0.000 title claims description 31
- 210000004369 blood Anatomy 0.000 title claims description 31
- 238000000034 method Methods 0.000 title description 16
- 238000002360 preparation method Methods 0.000 claims abstract description 47
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 168
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 109
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 99
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 96
- 239000007788 liquid Substances 0.000 claims description 55
- 239000013558 reference substance Substances 0.000 claims description 40
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 claims description 36
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 claims description 36
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 32
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 claims description 31
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 claims description 31
- 238000012360 testing method Methods 0.000 claims description 28
- 239000000047 product Substances 0.000 claims description 25
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 24
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 24
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 24
- 239000000706 filtrate Substances 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 21
- 239000000284 extract Substances 0.000 claims description 20
- 229930182494 ginsenoside Natural products 0.000 claims description 18
- 229940089161 ginsenoside Drugs 0.000 claims description 18
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 17
- 239000008517 radix Trichosanthis Substances 0.000 claims description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 16
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 16
- 238000003556 assay Methods 0.000 claims description 16
- 238000010828 elution Methods 0.000 claims description 16
- 239000000945 filler Substances 0.000 claims description 16
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims description 16
- 239000000377 silicon dioxide Substances 0.000 claims description 16
- 239000009636 Huang Qi Substances 0.000 claims description 15
- 238000005325 percolation Methods 0.000 claims description 14
- 239000002202 Polyethylene glycol Substances 0.000 claims description 9
- 239000002671 adjuvant Substances 0.000 claims description 9
- 229920001223 polyethylene glycol Polymers 0.000 claims description 9
- NSXFCODMXBYASQ-UHFFFAOYSA-N acetonitrile;oxolane;hydrate Chemical compound O.CC#N.C1CCOC1 NSXFCODMXBYASQ-UHFFFAOYSA-N 0.000 claims description 8
- 230000000274 adsorptive effect Effects 0.000 claims description 8
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 8
- 239000003480 eluent Substances 0.000 claims description 8
- 238000000105 evaporative light scattering detection Methods 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 8
- 239000003208 petroleum Substances 0.000 claims description 8
- 229920005989 resin Polymers 0.000 claims description 8
- 239000011347 resin Substances 0.000 claims description 8
- 229920006395 saturated elastomer Polymers 0.000 claims description 8
- 238000005303 weighing Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 5
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 claims description 4
- 235000005903 Dioscorea Nutrition 0.000 claims description 2
- 241000234273 Dioscorea Species 0.000 claims description 2
- 235000000504 Dioscorea villosa Nutrition 0.000 claims description 2
- 239000001828 Gelatine Substances 0.000 claims description 2
- 241000545442 Radix Species 0.000 claims description 2
- 235000004879 dioscorea Nutrition 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 150000003904 phospholipids Chemical class 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims description 2
- 238000003860 storage Methods 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims 2
- 239000012141 concentrate Substances 0.000 claims 1
- 239000002826 coolant Substances 0.000 claims 1
- 229940008099 dimethicone Drugs 0.000 claims 1
- 239000004205 dimethyl polysiloxane Substances 0.000 claims 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 238000002386 leaching Methods 0.000 claims 1
- 229940057995 liquid paraffin Drugs 0.000 claims 1
- 238000002844 melting Methods 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 238000010298 pulverizing process Methods 0.000 claims 1
- 239000006228 supernatant Substances 0.000 claims 1
- 239000009874 shenqi Substances 0.000 abstract description 11
- 229930182490 saponin Natural products 0.000 abstract description 2
- 150000007949 saponins Chemical class 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 229930195210 Ophiopogon Natural products 0.000 abstract 1
- 244000248557 Ophiopogon japonicus Species 0.000 abstract 1
- 241000405414 Rehmannia Species 0.000 abstract 1
- 241000218989 Trichosanthes Species 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 235000021028 berry Nutrition 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 30
- 230000007812 deficiency Effects 0.000 description 19
- 208000011580 syndromic disease Diseases 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 11
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- 230000010354 integration Effects 0.000 description 10
- 229940079593 drug Drugs 0.000 description 8
- 235000012054 meals Nutrition 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 102000001554 Hemoglobins Human genes 0.000 description 6
- 108010054147 Hemoglobins Proteins 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 238000010579 first pass effect Methods 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 206010013781 dry mouth Diseases 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 229940123208 Biguanide Drugs 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 229940127003 anti-diabetic drug Drugs 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 150000004283 biguanides Chemical class 0.000 description 2
- 230000023852 carbohydrate metabolic process Effects 0.000 description 2
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000002230 Diabetic coma Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010018687 Granulocytopenia Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020852 Hypertonia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010023379 Ketoacidosis Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000020965 cold beverage Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- -1 lipid peroxide Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940074869 marquis Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 229960005425 nitrendipine Drugs 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 206010029446 nocturia Diseases 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- VBUNOIXRZNJNAD-UHFFFAOYSA-N ponazuril Chemical compound CC1=CC(N2C(N(C)C(=O)NC2=O)=O)=CC=C1OC1=CC=C(S(=O)(=O)C(F)(F)F)C=C1 VBUNOIXRZNJNAD-UHFFFAOYSA-N 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229940093252 sorbitrate Drugs 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (12)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100806540A CN100333771C (en) | 2005-07-06 | 2005-07-06 | Ginseng and astragalis blood glucose loucring dorpping pill, and its preparing and detecting method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100806540A CN100333771C (en) | 2005-07-06 | 2005-07-06 | Ginseng and astragalis blood glucose loucring dorpping pill, and its preparing and detecting method |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1709439A true CN1709439A (en) | 2005-12-21 |
CN100333771C CN100333771C (en) | 2007-08-29 |
Family
ID=35705770
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100806540A Active CN100333771C (en) | 2005-07-06 | 2005-07-06 | Ginseng and astragalis blood glucose loucring dorpping pill, and its preparing and detecting method |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100333771C (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106344789A (en) * | 2016-08-29 | 2017-01-25 | 河南羚锐制药股份有限公司 | Production method of capsule made from traditional Chinese medicine for curing Type-IIdiabetes |
CN106526002A (en) * | 2016-10-12 | 2017-03-22 | 浙江工业大学 | Method for measuring content of Shenqi blood sugar reducing preparation and application thereof in overall quality control |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1245198C (en) * | 2004-09-17 | 2006-03-15 | 鲁南制药集团股份有限公司 | Chinese medicine composition for treating diabetes and its preparing method |
-
2005
- 2005-07-06 CN CNB2005100806540A patent/CN100333771C/en active Active
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106344789A (en) * | 2016-08-29 | 2017-01-25 | 河南羚锐制药股份有限公司 | Production method of capsule made from traditional Chinese medicine for curing Type-IIdiabetes |
CN106526002A (en) * | 2016-10-12 | 2017-03-22 | 浙江工业大学 | Method for measuring content of Shenqi blood sugar reducing preparation and application thereof in overall quality control |
CN106526002B (en) * | 2016-10-12 | 2019-04-09 | 浙江工业大学 | Ginseng-astragalus blood-sugar lowering preparation content determining method and its application in global quality control |
Also Published As
Publication number | Publication date |
---|---|
CN100333771C (en) | 2007-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100349598C (en) | Medicine for treating high lipemia and its production method | |
CN1686267A (en) | Chinese medicinal preparation for channel warming and blood nourishing and its preparation method | |
CN1245198C (en) | Chinese medicine composition for treating diabetes and its preparing method | |
CN100341492C (en) | Ginseng-astragalus blood-sugar lowering soft capsule, and its preparing and detecting method | |
CN1923241A (en) | Medicine composition containing epimedium extract, uncaria extract, and gastrodine, and its preparation and use | |
CN1679807A (en) | Heat-clearing and stranguria-relieving Chinese medicine preparation and production thereof | |
CN1698709A (en) | Compound preparation of baikal skullcap root | |
CN1679802A (en) | Preparation of strengthening waist and health-caring kidney and its making method | |
CN1709439A (en) | Ginseng and astragalis blood glucose loucring dorpping pill, and its preparing and detecting method | |
CN1698716A (en) | Gynecological Chinese medicinal preparation for stopping pain and expelling blood stasis | |
CN1294936C (en) | Medicine for treating diabetes and its preparation method | |
CN1112439A (en) | Chinese medicine for diabetes and its preparation | |
CN1813984A (en) | Chinese medicine preparation for treating liver disease and preparing method | |
CN1931233A (en) | Medicine composition of red sage and epimedium for treating cardiac and cerebral vascular diseases | |
CN1319560C (en) | Chinese medicine compound rheumatism preparation for improving bioavailability and medicine effect and preparing method | |
CN1879706A (en) | 'Shuang Huang Lian' dispersible tablet and preparation method thereof | |
CN100341490C (en) | Ginseng and astragalis blood glucose lowering dispersion tablet and its preparing and detecting method | |
CN1296080C (en) | Liver clearing blood pressure lowering capsule nd its preparation method | |
CN1864738A (en) | A medicine for treating angina pectoris | |
CN1698715A (en) | Heat-clearing abortion-preventing Chinese medicine and its preparation method | |
CN101040886A (en) | Medicine compound of erigeron breviscapus and tanshinone IIA sodium sulfoacid | |
CN1481808A (en) | Efficacious parts compositions for prevention and cure of senile dementia and preparation method | |
CN1736429A (en) | Blood stasis dispelling dripping pills for treating coronary heart disease, angina pectoris and hyperlipemia and preparation process thereof | |
CN1287835C (en) | Pharmaceutical composition for treating coronary heart disease and angina pectoris and its preparing process | |
CN1872258A (en) | Chinese traditional medicine for treating chronic hepatitis, and preparation method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: LUNAN HOPE PHARMACEUTICAL Co.,Ltd. Assignor: LUNAN PHARMACEUTICAL Group Corp. Contract record no.: 2010370000516 Denomination of invention: Ginseng and astragalis blood glucose loucring dorpping pill, and its preparing and detecting method Granted publication date: 20070829 License type: Exclusive License Open date: 20051221 Record date: 20100909 |
|
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: LUNAN HOPE PHARMACEUTICAL Co.,Ltd. Assignor: LUNAN PHARMACEUTICAL Group Corp. Contract record no.: 2010370000516 Date of cancellation: 20131016 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20211213 Address after: 276006 No. 209 Hongqi Road, Shandong, Linyi Patentee after: LUNAN HOPE PHARMACEUTICAL Co.,Ltd. Address before: 276005 No. 209 Hongqi Road, Shandong, Linyi Patentee before: LUNAN PHARMACEUTICAL Group Corp. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: The invention relates to a Shenqi Jiangtang dropping pill and a preparation and detection method thereof Effective date of registration: 20211228 Granted publication date: 20070829 Pledgee: China Construction Bank Corporation Linyi Shizhong sub branch Pledgor: LUNAN HOPE PHARMACEUTICAL Co.,Ltd. Registration number: Y2021980016801 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230331 Granted publication date: 20070829 Pledgee: China Construction Bank Corporation Linyi Shizhong sub branch Pledgor: LUNAN HOPE PHARMACEUTICAL Co.,Ltd. Registration number: Y2021980016801 |